Recursion and Genentech report the first validated neuroscience target found by AI. Learn how CRISPR, cellular imaging and supercomputing made it possible and what comes next.
Recursion and Genentech Validate First AI-Discovered Neuroscience Target Read More »
A concise expert view on AI in drug discovery: how ML evolved into GenAI, key barriers like workflow integration and LLM costs, and practical steps for researchers.
AI in Drug Discovery: Hype, Practical Limits and First Steps for Scientists Read More »
Verseon’s physics-first Deep Quantum Modeling designs novel drug chemistries beyond AI training limits, creating candidates for lower-bleeding anticoagulants and diabetic eye disease.
Physics-First Drug Design: How Verseon Builds New Medicines Beyond AI Training Data Read More »
Explore how AI is transforming drug discovery — from target ID to smarter clinical trials — cutting time and cost while improving patient outcomes. A concise outlook for healthcare leaders and investors.
AI Drug Discovery: How Machine Learning Is Speeding Up New Medicines Read More »
A concise, realistic guide to where AI adds measurable value in drug discovery: data enrichment, experiment prioritization, and multi-parameter optimization. Practical limits and steps for teams.
AI in Drug Discovery: Practical Value, Not Hype Read More »
How generative AI and protein structure prediction are shortening drug discovery timelines, with examples, practical impacts, and strategic considerations for pharma leaders.
Generative AI Meets Structure Prediction: Faster Drug Discovery for Pharma R&D Read More »
How Insilico Medicine’s Pharma.AI fuses foundation models, AI agents, Generative Biologics, Chemistry42, PandaClaw and MMAI Gym to speed drug discovery.
How AI is shortening drug discovery timelines, producing real candidates and reshaping R&D with examples from AlphaFold, Exscientia, BenevolentAI and Insilico.
AI’s Proven Track Record: Accelerating Drug Discovery from Lab to Life Read More »
Concise overview of AI in drug discovery: where it delivers, measurable early-stage gains, and the validation and reproducibility hurdles slowing broader adoption.
AI in Drug Discovery: Progress and Persistent Challenges Read More »
Agentic AI is reshaping drug discovery. Learn why specialized agents outperform general models, how they tackle preclinical toxicology, and how teams can start pilots today.
The Rise of Agentic AI: How Specialized Agents Are Accelerating Drug Discovery Read More »
